Fundraising FoxIQ Capital — 2026 Investments
5 investments dated 2026 · listed companies and verified rows first · show all
IMU Biosciences builds an immune-system analysis platform that measures over 100 million datapoints from a single blood sample across large patient populations, an approach it calls HD Immunology.
AI & Machine LearningBiotechHealthtechLondon, GB
Thomas Hayday PhD(Co-founder & Chief Research Officer)Adam Laing PhD(Co-founder & Chief Scientific Officer)Mario Cantero MBA(Co-founder & Chief Operating Officer)Adam Laing(Founder)inJohn Baker PhD(Chief Executive Officer)
Co-investorsElderstreet InvestmentsExpaKfundLifeX VenturesMolten Ventures
Nuclear Turbines develops advanced modular nuclear generation systems in which a reactor directly heats compressed air to drive a commercial gas turbine, targeting low-cost electricity.
CleantechDeep TechEnergy
Co-investorsEmpirical VenturesRhapsody Venture PartnersZero Carbon CapitalZero Carbon Capital
RevEng.AI builds a verification platform for software supply chain integrity using AI models trained on binary analysis to identify vulnerabilities, malware, and security threats in released software in production.
AI & Machine LearningCybersecurityDeveloper Tools
James Patrick-Evans(CEO and Founder)in
Co-investorsEpisode1In-Q-TelOsney Capital
RoundUp.org lets donors link a credit card to automatically round up everyday purchases to the next dollar and donate the spare change to a nonprofit of their choice.
FintechImpact & Social Good
Jed Carlson(Founder / CEO)in
Co-investorsDuke Capital PartnersSilverton Partners.406 VenturesAlbum VCKarma VenturesSMBC Asia Rising Fund
Turbine provides financing that lets venture capital firms and their limited partners borrow against fund positions and carried interest instead of selling them, giving GPs and LPs access to liquidity while retaining ownership.
Fintech
Mike Hurst(Founder & CEO)in
Co-investorsAlpha EdisonTTV CapitalB Capital GroupB4 CapitalEvolution VenturesStartX+6 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.